Malaysian Health Technology Assessment Section’s Post

HTA Protocol Meeting 9 January 2025 BM 1, Block E1, MOH We are excited to announce the successful presentation of our protocol for evaluating monoclonal antibody therapies (Ofatumumab, Rituximab, Ocrelizumab) for relapsing Multiple Sclerosis (rMS) to our expert committee during a productive virtual session held today. The expert consists of the Neurologist, Physicians and Pharmacist from government and academic sectors. This initiative follows a meticulous Health Technology Assessment (HTA) work process, which began with the identification and prioritization of this critical topic. This topic has been prioritized for HTA in the HTA-CPG Council 1/2023 meeting. Protocol development followed subsequently in the HTA work process, defining the scope of assessment. A dedicated expert committees are elected to provide technical input on the subject being assessed. Following that, in-depth systematic review of scientific evidence and local economic evaluations will be conducted. Our protocol presentation marked a significant milestone in this process, focusing on the therapies' effectiveness, safety, cost implications, and broader impacts including organizational, social, ethical and legal. The virtual platform provided an opportunity for insightful discussions, ensuring the protocol and hence the assessment provide meaningful recommendations and answering the policy questions, further facilitating its adoption. We are immensely grateful for the Expert Committee valuable input and are committed to advancing this project to enhance the delivery of high quality care for patients with rMS in this country. #HealthTechnologyAssessment #mahtas #bahagianperkembanganperubatan #kementeriankesihatanmalaysia

  • No alternative text description for this image
  • No alternative text description for this image
  • No alternative text description for this image
  • No alternative text description for this image
  • No alternative text description for this image
    +3

To view or add a comment, sign in

Explore topics